Melissa B. Davis, PhD, on Thursday addressed the challenges of unraveling social versus biological drivers of racial disparities in cancer outcomes.
Data from the phase 3 MSB-GVHD001 trial support the FDA approval of rememstemcel-L in pediatric SR-aGVHD.
Join us for this social media event on treating estrogen receptor (ER)-positive / HER2-negative metastatic breast cancer designed to encourage the exchange o…
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to…
Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.
$700,000 over three years for female associate professors performing research that has a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis,…
Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, according to experts.
Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.
Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.
Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.
